Fig. 2

Survival analysis for the different experimental groups. Significant decrease in survival of PDE3A KO mice treated with LPS compared with the WT, PDE3A KO, and LPS-treated WT mice while studying the effect of genetic deletion of PDE3A on inflammation-induced CMH development (a). No difference in the survival between any experiment groups while studying the effect of pharmacological inhibition of PDE3A with cilostazol on CAA-associated CMH development (b). LPS treatment caused a significant reduction in survival in the WT and WT-CIL treated mice compared with PBS-treated WT mice while studying the effect of pharmacological inhibition of PDE3A with cilostazol on inflammation-induced CMH development (c). Statistical test: Log-rank test for survival analysis. #p < 0.05 compared with WT, PDE3A KO, and LPS-treated WT, *p < 0.05 compared with WT-PBS